TMCnet News

Global Genetic Diseases, Cancer, Forensic & Paternity Molecular Diagnostic Testing Markets Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Affymetrix, Biokit, Dia - Research and Markets
[March 25, 2016]

Global Genetic Diseases, Cancer, Forensic & Paternity Molecular Diagnostic Testing Markets Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Affymetrix, Biokit, Dia - Research and Markets


Research and Markets (http://www.researchandmarkets.com/research/gql6nb/20162020_world) has announced the addition of the "2016-2020 World Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing Markets: Country Forecasts, Emerging Technologies, Competitive Landscape" report to their offering.

This new seven-country study contains 570 pages, 42 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products in testing for genetic diseases, cancer, as well as forensic and paternity/HLA typing applications during the next five years.

Key Topics Covered:

  • Market shares of leading suppliers
  • Business and technological trends in major markets
  • Five-year test volume and sales forecasts
  • Market shares of leading competitors
  • Feature comparison of major analyzers
  • Strategic profiles of leading market players and start-up firms developing innovative products
  • Specific product and business opportunities for instrument and consumable suppliers.



Genetic Diseases, Cancer, Forensic and Paternity molecular diagnostic testing markets are among the most rapidly growing segments of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.


Contains 570 pages and 42 tables

Companies Mentioned:

  • Abbott
  • Affymetrix
  • Agilent Technologies (News - Alert)
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biokit
  • bioMerieux
  • Bio-Rad
  • Biotest
  • Cepheid
  • CellMark Forensics/LabCorp
  • Decode Genetics
  • Dia

For more information visit http://www.researchandmarkets.com/research/gql6nb/20162020_world


[ Back To TMCnet.com's Homepage ]